HIGHFDA DRUG

Alembic Pharmaceuticals Recalls Fesoterodine Tablets for Impurity Risk

Alembic Pharmaceuticals Limited recalled Fesoterodine Fumarate, Extended-release Tablets after discovering high levels of a harmful impurity. The recall affects approximately 30,000 tablets distributed nationwide. Consumers must stop using the medication immediately and consult their healthcare providers.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
December 16, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
December 16, 2025
Hazard Level
HIGH
Brands
FESOTERODINE FUMARATE, Alembic Pharmaceuticals
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
FESOTERODINE FUMARATE, Alembic Pharmaceuticals
Product type
Fesoterodine Fumarate Tablets
Model numbers
Lot# 2405003360, Exp Date: Jan 31, 2026
UPC codes
62332-175, 62332-176, 62332-175-30, 62332-175-90, 62332-175-91, 62332-175-10, 62332-176-30, 62332-176-90 +3 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    December 16, 2025

  2. Reported by FDA DRUG

    January 14, 2026

  3. RecallRadar source check

    January 21, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Alembic Pharmaceuticals Limited or your healthcare provider for guidance

About This Product

Fesoterodine Fumarate is a medication used to treat overactive bladder symptoms such as urgency and frequency of urination. Consumers typically buy this medication to manage these urinary conditions, often prescribed by healthcare professionals.

Why This Is Dangerous

The recall involves high levels of a chemical impurity known as 'Diester Impurity,' which can pose health risks if ingested. This impurity exceeds the safety specifications set for the medication and necessitates the recall.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers should stop using the medication immediately, which could lead to the need for alternative treatments. The recall may cause inconvenience for those relying on the medication for managing their condition.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number on your medication packaging.
  2. Verify the expiration date, which should be January 31, 2026.
  3. If the lot number matches 2405003360, your product is affected.

Where to find product info

You can find the lot number on the bottle label or packaging of the tablets.

What timeline to expect

Expect a refund or replacement processing time of 4-6 weeks after returning the product.

If the manufacturer is unresponsive

  • Contact the company again using their customer service number.
  • File a complaint with the FDA if no response is received.

How to prevent similar issues

  • Look for medications with clear labeling and impurity testing certifications.
  • Consult healthcare providers for recommendations on safe alternatives.
  • Research recalls and safety alerts for medications regularly.

Documentation advice

Document any communications with Alembic Pharmaceuticals and keep copies of receipts or purchases related to the product.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Fesoterodine Fumarate, Extended-release Tablets, 8 mg, sold in 30-tablet bottles. The affected lot number is 2405003360, with an expiration date of January 31, 2026. Products were manufactured in Gujarat, India, and distributed across the U.S. and Puerto Rico.

Key Facts

  • Recalled due to high levels of a chemical impurity
  • Stop using the product immediately
  • Consult healthcare providers for further guidance
  • Distributed nationwide in the U.S. and Puerto Rico
  • Affected lot number: 2405003360

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeFesoterodine Fumarate Tablets
Sold At
Multiple Retailers

Product Details

Model Numbers
Lot# 2405003360
Exp Date: Jan 31, 2026
UPC Codes
62332-175
62332-176
62332-175-30
+8 more
Affected States
ALL
Report Date
January 14, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more